Altre lingue StemRIM

Azioni

4599

JP3399690001

Tempo differito Japan Exchange Altri mercati azionari 08:00:00 13/05/2024			Variaz. 5gg	Var. 1 gen.
462 ^JPY	-1,70%		-3,55%	-20,07%

13/03	StemRIM annuncia l'avvio della sperimentazione clinica di Fase 2 per Redasemtide nella cardiomiopatia ischemica	CI
31/01	StemRIM Inc. annuncia la registrazione di un brevetto (Russia) per l'uso del peptide del frammento HMGB1, come ulteriore indicazione terapeutica dei disturbi della cartilagine	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	09/05
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	13/03
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	31/01
StemRIM Allocates 300 Stock Options to R&D Partner	29/12
StemRIM to Issue Stock Acquisition Rights	14/12
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation	07/12
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co	04/12
StemRIM Issues 433,000 Shares as Restricted Stock Compensation	17/11
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration	17/11
StemRIM Discloses Issuance Details of Stock Options to Directors	20/09/23
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide	06/09/23
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction	04/09/23
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke	31/07/23
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China	25/07/23
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction	18/07/23
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023	19/06/23
Shionogi & Co., Ltd. - Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa	24/05/23
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy	16/05/23
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke	28/04/23
StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results	12/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue StemRIM

Azioni

4599

JP3399690001

Altre lingue

Filtri